the aim of the study was the non-inferiority of raltitrexed as compared with standard 5fluorouracil-folinic acid as adjuvant chemotherapy for radically resected colon cancer patients. 993 patinets have been randomized; the enrollement was prematurely closed when 17 raltitrexed-related deaths were recorded. The toxicity was higher in patinets treated with raltitrexed. RSF and OAS were slight inferion in patinets treated with raltitrexed. In conclusion, the study failed to demonstrate the non-inferiority of raltitrexed.
Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) / Popov, I; Carrato, A; Sobrero, A; Vincent, M; Kerr, D; Labianca, R; Bianco, Ar; El Serafi, M; Bedenne, L; Paillot, B; Mini, E; Sanches, E; Welch, J; Colette, L; Praet, M; Wils, J; Carlomagno, Chiara. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 44:(2008), pp. 2204-2211.
Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
CARLOMAGNO, Chiara
2008
Abstract
the aim of the study was the non-inferiority of raltitrexed as compared with standard 5fluorouracil-folinic acid as adjuvant chemotherapy for radically resected colon cancer patients. 993 patinets have been randomized; the enrollement was prematurely closed when 17 raltitrexed-related deaths were recorded. The toxicity was higher in patinets treated with raltitrexed. RSF and OAS were slight inferion in patinets treated with raltitrexed. In conclusion, the study failed to demonstrate the non-inferiority of raltitrexed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
